Member Info for Ducati2

https://www.marketscreener.com/quote/stock/SYNAIRGEN-PLC-4004905/news/COVID-19-Clinical-Programme-Update-32042714/

https://www.ii.co.uk/analysis-commentary/best-aim-stocks-2020-ii514584

Synairgen (LSE:SNG) was another hugely popular stock. Its shares rose 2,420% across 2020 after the respiratory drugs company disclosed positive results on a potential treatment for hospitalised Covid-19 patients. Phase III trial sites are now being set up in the UK and the former University of Southampton spin-off anticipates dosing the first patients soon.

The jump in shares since July means Synairgen is now worth £300 million

Approved!,

https://www.globalbankingandfinance.com/category/news/covid-19-clinical-programme-update-2/

https://www.dailymail.co.uk/news/article-9067979/Tennessee-nurse-faints-live-air-minutes-getting-Pfizers-COVID-19-vaccine.html

https://www.proactiveinvestors.co.uk/companies/news/936925/synairgen-speeds-up-the-trial-of-potential-coronavirus-treatment-936925.html

Could be good timing as the U.K. trial will be full...........more contagious less deaths !

https://www.dailymail.co.uk/news/article-9054663/Minister-urges-families-minimum-Christmas-bubbles.html

Activ-2..........the only thing missing from Dr FAuci is the mention of.....

https://www.youtube.com/watch?v=gU03eyVykXQ&feature=youtu.be

https://www.riseabovecovid.org/en/about-us/study-news/

How many strains........

https://news.sky.com/story/covid-19-should-we-be-worried-about-coronavirus-mutating-and-could-it-affect-the-vaccine-12161566

https://www.dailymail.co.uk/sciencetech/article-9051983/Antibiotic-azithromycin-DROPPED-RECOVERY-trial.html

Professor Peter Horby, RECOVERY lead at the University of Oxford, said: 'Azithromycin has been widely used to treat COVID patients because of its theoretical potential to reduce lung inflammation.

'Our results show very clearly that for patients hospitalised with COVID-19 azithromycin is not an effective treatment.

'While that is disappointing, it is nonetheless an important result that will guide clinical care around the world.

'Looking ahead, RECOVERY continues to study several promising treatments, including convalescent plasma and Regeneron's antibody ****tail targeted at the virus. Further results are likely over the next couple of months.'

The most recent findings have been published online at the pre-print server medRxiv but have not yet been peer-reviewed.

The potential treatments left in the trial are: dexamethasone, colchicine, tocilizumab, convalescent plasma, REGN-COV2 (a combination of monoclonal antibodies directed against coronavirus) and aspirin.

No drugs are currently able to cure Covid-19, although the trial did discover the steroid dexamethasone can reduce the risk of death among the most seriously ill.

https://www.theguardian.com/politics/live/2020/dec/14/brexit-covid-coronavirus-boris-johnson-uk-news-live-updates

Tier 3, they might show some interest in a Therapeutic!

https://www.bbc.co.uk/news/uk-wales-55299862

Antibodies are proteins that are released by cells of the immune system. They disable viruses by latching on to their surface proteins and preventing them gaining access to the body’s cells.

https://www.theguardian.com/science/2020/dec/13/autoantibodies-may-be-driving-severe-covid-cases-study-shows

https://infectagentscancer.biomedcentral.com/articles/10.1186/s13027-020-00338-z
U.S. Food and Drug Administration therapeutic approval process
The 1906 Pure Food and Drug Act is the foundation for the modern FDA [21]. The primary responsibility of the FDA is to ensure the safety and efficacy of medical drugs, tests, and devices delivered to consumers in the United States. A rigorous drug development process exists to uphold these standards. The traditional drug development process occurs in stages: discovery and development, preclinical research, clinical trials, FDA review, and post marketing surveillance [22]. On average, it takes 10–12 years to bring a drug from the lab bench to the consumer market in the USA [23]. Statistical studies analyzing drug development have shown only 9.6 to 13.8% of drug candidates are eventually FDA-approved (Fig. 1) [24]. The role of the FDA in drug development focuses on safety, mechanism of action, and efficacy involving clinical therapeutic use.

https://www.nihr.ac.uk/news/covid-19-treatment-results-published-in-journal-ahead-of-nihr-supported-phase-3-trial-of-nebulised-interferon-beta/26186

Hope Han**** gets the Message.........Loud and clear, just might wake up to the fact that its on his door step.

https://mobile.twitter.com/MattHan****

Prion25.........Same as the rest of the World, how do you say Synairgen. You know that Therapeutic company in the U.K.

SNG001.......They might as well mention it.......Take a deep breath they waking up to what’s on offer.

https://www.dailymail.co.uk/sciencetech/article-9043703/Five-genes-severe-cases-Covid-19.html

The harsh reality will soon hit,that the vaccines last.........how long!

With the cold spell just starting, the Vaccine will not stop the rapid spread of Covid and the US, Canada are just in a sorry place. The U.K. have the Vaccine with their finger in the air hoping the wind blows in the correct direction.

A deeply entrenched idea, that newly emerged agents of disease inevitably evolve to become more benign over time, is scientifically unfounded, according to new research.

They can, in fact, become more virulent depending on the conditions, and the easier it is for a virus to spread, the more likely it is to do so.

The findings suggest that failing to control outbreaks of Covid-19 – or even deliberately encouraging the circulation of the Sars-CoV-2 virus that causes it, as some lockdown sceptics have proposed – could increase the the chance of more harmful forms of the virus emerging in the short term.

Public health experts have been warning for months that trying to achieve herd immunity by letting the virus circulate more-or-less freely is dangerous because it could lead to unnecessary deaths and health services being overwhelmed. However, they have not generally taken into account the possibility that it could make the disease more lethal – at least until sufficient immunity has built up in the human population.

Since the 1980s, evolutionary biologists have predicted an association between the virulence and transmissibility of a novel pathogen, based on theoretical models.